Merck and Moderna's Cancer Vaccine Beat Keytruda. The Harder Test Is Manufacturing.

Intismeran autogene plus Keytruda reduced the risk of melanoma recurrence or death by 42% versus Keytruda alone, according to Phase 3 data presented at ESMO 2026. The combination also reduced the risk of cancer spreading to distant parts of the body or death by 38% versus the immunotherapy alone, at a median follow-up of about two years. Moderna shares still fell as much as 25% that day before regaining some ground.

The readout is a scientific milestone. A Merck release called INTerpath-001 the first positive Phase 3 result for an individualized neoantigen therapy and for an mRNA-based cancer therapy, and the first Phase 3 to show a clinically meaningful improvement over Keytruda alone in the adjuvant setting for resected melanoma. Investors sold the stock anyway, because the product has to be manufactured from scratch for every patient.

A 1,137-patient test against Keytruda

INTerpath-001 (NCT05933577) is a randomized, double-blind, placebo- and active-comparator-controlled global Phase 3 trial of intismeran autogene (mRNA-4157/V940) plus Keytruda versus Keytruda alone in patients with completely resected, high-risk stage IIB, IIC, III, or IV cutaneous melanoma. The trial enrolled 1,137 patients, randomized 2:1 to the combination versus Keytruda alone, and met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival. Overall survival remains immature and the trial will continue to evaluate it.

The regimen is intismeran 1 mg every three weeks for up to nine doses, plus Keytruda 400 mg every six weeks for up to nine cycles, or about one year. Each intismeran dose is an mRNA encoding up to 34 neoantigens, tailored to the unique mutational signature of an individual patient's tumor.

Why the curves separate after six months

The combination showed little difference from Keytruda alone during the first six months. A separate analysis showed a 58% reduction in the risk of recurrence or death after that six-month mark. One trial investigator attributed the delay to custom manufacturing, a process that can take roughly six weeks while patients start Keytruda in the meantime, though he cautioned the explanation is a hypothesis rather than proof.

Partial data leaked on social media on Thursday, October 22, prompting the companies to release detailed results early that day. Moderna shares are up nearly 600% this year on cancer-shot optimism, so even a positive readout could land as a miss versus the tape. RBC Capital Markets analyst Trung Huynh wrote that investors had hoped the Phase 3 would replicate the Phase 2's roughly 49% reduction, and that the result landed at the low end of expectations, though it is clinically meaningful and likely to support approval.

That bar was high. Prior Phase 2b results from KEYNOTE-942/mRNA-4157-P201 at five-year follow-up showed a 49% reduction in risk of recurrence or death (HR 0.51) and a 59% reduction in risk of distant metastasis or death (HR 0.411) versus Keytruda alone. The Phase 3 reductions of 42% and 38% still beat Keytruda, but they sat below the Phase 2 figure investors had hoped to see again.

One vaccine, one patient, no inventory

Dr. Adil Daud of UCSF, the lead investigator, noted the therapy is "super labor-intensive" because you cannot stockpile vaccines and must make one for each person, and said "it's probably going to cost like a lot of money." Six melanoma specialists said the results are a clinically meaningful advance that could become a standard of care for patients who have surgery first without prior immunotherapy.

Moderna CEO Stephane Bancel said the company is finishing a regulatory filing and aims for full approval next year. Merck is preparing for the eventual loss of Keytruda patent protection, and pairing the checkpoint inhibitor with a personalized vaccine is one way to defend that franchise. It also ties the commercial case to a manufacturing model that cannot warehouse product.

The INTerpath clinical program spans nine Phase 2 and Phase 3 trials across melanoma, non-small cell lung cancer, bladder cancer, and renal cell carcinoma, plus earlier studies in pancreatic, gastric, and perioperative NSCLC. Whether the delayed benefit seen here justifies a custom manufacturing chain will be tested in those other tumor types.

INTerpath-001 answered the efficacy question that the Phase 2 results only raised. The remaining problem is operational: a therapy encoded to one patient's tumor, produced on a roughly six-week clock, on top of a drug that already works after surgery. The clinical results cleared their bar. Manufacturing still has to clear its own.